Pembrolizumab in Elderly Patients With Advanced Lung Cancer

Summary

This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing Programmed death-ligand 1 (PD-L1). 82 patients will be enrolled in this trial to examine the efficacy, the impact on geriatric assessments, the quality of life and the self-reported outcomes.

Timeline

Start

2017-01-15

Primary completion

2023-04-28

Completion

2023-07-15

Drugs

Indications